MannKind (NASDAQ:MNKD) announces the completion of construction of a new high-potency manufacturing suite in its Danbury, CT facility.
The expansion will enable the company to produce dry powder formulations of ingredients such as epinephrine on a commercial scale.
Shares are up 5% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.